A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

被引：0
|
作者：
Landen, Charles N.
Buckanovich, Ronald J.
Sill, Michael
Mannel, Robert S.
Walker, Joan L.
Disilvestro, Paul
Mathews, Cara Amanda
Mutch, David Gardner
Hernandez, Marcia
Martin, Lainie P.
Bishop, Erin
Gill, Sarah
Gordinier, Mary E.
Burger, Robert Allen
Aghajanian, Carol
Liu, Joyce F.
Moore, Kathleen N.
Bookman, Michael A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Gynecol Oncol Grp Stat & Data Ctr, Buffalo, NY USA
[4] Stephenson Canc Ctr, Oklahoma City, OK USA
[5] Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA
[6] Women Infants Hosp, Providence, RI USA
[7] Brown Univ, Women & Infants Hosp, Dept Obstet & Gynecol, Program Womens Oncol, Providence, RI USA
[8] Washington Univ St Louis, Sch Med, St Louis, MO USA
[9] Mercy Hosp Springfield, Springfield, MO USA
[10] Univ Pennsylvania, Abramson Canc Ctr, Philadelphia, PA USA
[11] Froedtert & Med Coll Wisconsin, Milwaukee, WI USA
[12] Nancy N & JC Lewis Canc & Res Pavil, Savannah, GA USA
[13] Louisville Oncol, Louisville, KY USA
[14] Univ Pennsylvania, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Dana Farber Canc Inst, Boston, MA USA
[17] Univ Oklahoma Hlth Sci Ctr, Div Obstet & Gynecol, Dept Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA
[18] Univ Arizona, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5501
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Dhillon, Sohita
    BIODRUGS, 2013, 27 (04) : 375 - 392
  • [22] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [23] Surgical Risk Score Predicts Suboptimal Debulking or a Major Perioperative Complication in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Stashwick, Caitlin
    Post, Miriam D.
    Arruda, Jaime S.
    Spillman, Monique A.
    Behbakht, Kian
    Davidson, Susan A.
    Kelly, Michael Greg
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (08) : 1422 - 1427
  • [24] PROSPECTIVE FEASIBILITY STUDY OF NEOADJUVANT DOSE-DENSE PACLITAXEL PLUS CARBOPLATIN WITH BEVACIZUMAB THERAPY FOR ADVANCED OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PATIENTS
    Nomura, H.
    Iwasa, N.
    Kataoka, F.
    Chiyoda, T.
    Yamagami, W.
    Fujii, T.
    Aoki, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A150 - A150
  • [25] Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy
    Liu, Marisa C.
    Sutedja, Joyce
    Tewari, Krishnansu S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (05) : 475 - 480
  • [26] Phase I/II study of weekly paclitaxel with or without alisertib, an investigational aurora a Kinase inhibitor: phase I results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer
    Falchook, G.
    Goff, B.
    Kurzrock, R.
    Gray, H.
    Martin, L.
    Coleman, R.
    Xiao, H.
    Zhou, X.
    Benaim, E.
    Schilder, R.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S31 - S32
  • [27] A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Konner, Jason
    Schilder, Russell J.
    DeRosa, Felicia A.
    Gerst, Scott R.
    Tew, William P.
    Sabbatini, Paul J.
    Hensley, Martee L.
    Spriggs, David R.
    Aghajanian, Carol A.
    GYNECOLOGIC ONCOLOGY, 2008, 110 (02) : 140 - 145
  • [28] Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
    Bodnar, Lubomir
    Gornas, Maria
    Szczylik, Cezary
    GYNECOLOGIC ONCOLOGY, 2011, 123 (01) : 33 - 36
  • [29] Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S104 - S104
  • [30] Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 364 - 369
12345